Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 30, 2020 (7 years ago)

Glycopyrrolate Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specification: Presence of unknown impurity observed.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Glycopyrrolate Tablets, USP 1 mg, 100-count bottle, Rx only, Dist. by: Par Pharmaceutical, Chestnut Ridge, NY, 10977, U.S.A, Mfg. by: Par Formulations Private Limited, 1/58, Pudupakkam, Kelambakkam - 603 103., Made in India NDC# 49884-0065-01

Affected NDC 49884-0065-01

Compare with the code on your package — it is the most precise check available.

Drug: Glycopyrrolate

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Glycopyrrolate
NDC 49884-0065
1 mg/1 Tablet
Oral
Par Health USA, LLC Rx
Recalling firm
Par Pharmaceutical Inc.
NDC code
49884-0065-01
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1071-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Glycopyrrolate recalls

See all
Class II · Moderate risk

Glycopyrrolate

Lack of Assurance of Sterility: Leaking/damaged syringes.

Ongoing Sterility / contamination Denver Solutions, LLC DBA Leiters Health NDC 71449-104-11 D-0370-2025

Other recalls by Par Pharmaceutical Inc.

All 2020 recalls
Class III · Low risk

PrediniSONE Tablets

Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-5337-31 D-1035-2020
Class III · Low risk

Frovatriptan Succinate Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date of April 2022.

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-3718-34 D-0843-2020